Wall Street analysts say the Pfizer and Moderna Kovit-19 vaccine will generate $ 32 billion in revenue – next year alone. Pfizer (PFE) predicts that the Covit-19 vaccine will generate $ 19 billion in revenue by 2021, according to Morgan Stanley. This is estimated to be $ 975 million in 2020 vaccine revenue. Pfizer will split its proceeds with German company Bioendech (PNTX) to develop the vaccine. A panel of FDA advisers on Thursday recommended granting emergency use authorization to the vaccine candidate created by the pair. U.S. officials say they are acting “quickly” to give the vaccine a green light. As the world continues to vaccinate, Pfizer is expected to surpass $ 9.3 billion in combined Covit-19 vaccine revenue in 2022 and 2023, Morgan Stanley predicts. Vaccine advances did not boost Pfizer’s stock price because the pharmaceutical manufacturer was already a large company. Shares of Pfizer have risen just 12% this year, outpacing the S&P 500’s 13.5% overall profit. However, Pfizer’s expected revenue in 2021 will be higher than the company’s sales last year: the pneumonia vaccine grossed $ 5.8 billion. Nearly 300%, raising the value of German biotech to nearly $ 30 billion. Last year Moderna had just $ 60 million in revenue. Meanwhile, Moderna’s Govt-19 vaccine candidate has turned an already unknown company into a $ 62 billion powerhouse. Shares have risen nearly 700% this year, and Morgan Stanley estimates that half of the company’s market value is linked to the vaccine. Goldman Sachs estimates that Moderna will generate $ 13.2 billion in revenue from the Govt-19 vaccine next year. Others are very positive. According to Morgan Stanley, investors expect the company to earn $ 10 billion to $ 15 billion from the sale of the Covit-19 vaccine in 2021 and 2022, following a surge in billions in booster sales. These are huge sums for a company that earned just $ 60 million in sales in 2019 and had never licensed a product before. “It’s epic,” said Alan Carr, Neetham’s biotech analyst. “It’s a historic achievement in drug development. It’s hard to imagine a young company like this taking on a new technology and preparing it in time for the worst epidemic of a century.” Wall Street Moderna’s Pipeline Both Pfizer and Moderna have released data indicating that their vaccine candidates are the most effective in preventing Covit-19 – more than researchers expected. Investors believe the achievement confirms Moderna’s MRNA technology, which seeks to use normal biological processes to create the desired therapeutic effect. Wall Street now has more confidence in Moderna’s entire pipeline, betting it won’t be the company’s only blockbuster. Moderna’s corona virus vaccine “technology has proven to be safe and effective, opening up the potential of other vaccines in the pipeline,” Morgan Stanley researcher Matthew Harrison wrote in a recent note to clients. More than a quarter of Modernna’s market value is now allocated to its other MRNA vaccines, Morgan Stanley estimates. Now the big debate on Wall Street is how long the Govt-19 vaccines will be revenue for these companies. It is not yet known how long the treatments will provide protection and how many times individuals should receive booster shots.Harrison said it will take at least a few years of follow-up data to understand how effective boosters are. At that time, public health officials are likely to encourage high-risk and elderly people to raise, he said. The debate over profitability during the health crisis could be a game changer for medical advances in the global economy, and could lead to the recovery of airlines, hotels, casinos, restaurants and other sectors devastated by the epidemic. These vaccines will eventually lead to the restructuring of millions of workers who lost their jobs during the health crisis. Still, the multi-billion dollar Pfizer and Moderna vaccine production critique of human suffering. The epidemic has killed nearly 300,000 people in the United States alone. Competitive pharmaceutical manufacturers Johnson & Johnson (JNJ) and AstraZeneca (AZN) have promised to make their vaccines available on a non-profit basis during infections. “It’s completely wrong for pharmaceutical companies like Pfizer and Moderna to make a profit, and it’s very wrong for US executives to gain personal wealth from U.S. taxpayers who are heavily subsidized and supported by the Cowit-19 vaccine,” said spokesman Eli Jupnick, a progressive watchdog and patient advocacy group. To .US. Neither Fischer nor Moderno responded to requests for comment. In a statement last month, Pfizer said that the development and production costs of its Govt-19 vaccine were “completely self-funded, with billions of dollars already invested at risk.” Said. The federal government agreed to pay $ 1.95 billion for the first 100 million doses, although it did not accept Pfizer’s money from Operation Warp Speed, the Trump administration’s vaccine initiative. The deal served as a safety net for Pfizer, providing the company with a lucrative guaranteed market if the FDA gives its blessing to the vaccine. Moderna hit the capital markets for some funds. In May, the company raised $ 1.3 billion through a share sale. Some Modern executives had tens of thousands of dollars in reserves through pre-planned transactions, yet raised eyebrows from former SEC executives. Moderna also took a portion of the taxpayer money to develop her vaccine candidate. The federal government provided a grant of about $ 955 million to Moderna. Moderna worked closely with government scientists to test its vaccine. The length analyst said the upcoming revenue for Car, Moderna and Pfizer will boost the factors that make medical advances possible. “There’s nothing like a revenue stream to promote them,” he said. .
Source